Carregant...
TRAIL activates JNK and NF-κB through RIP1-dependent and -independent pathways
The death receptor (DR) ligand TRAIL is being evaluated in clinical trials as an anti-cancer agent; however, many studies have found that TRAIL also enhances tumor progression by activating the NF-κB pathway in apoptosis-resistant cells. Although RIP1, cFLIP and caspase-8 have been implicated in TRA...
Guardat en:
| Publicat a: | Cell Signal |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4276503/ https://ncbi.nlm.nih.gov/pubmed/25446254 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cellsig.2014.11.014 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|